Announcements in Conjunction With Theratechnologies Annual Meeting
May 13 2021 - 11:15AM
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH)
(NASDAQ: THTX), a biopharmaceutical company focused on the
development and commercialization of innovative therapies, today
held its annual meeting of shareholders.
As part of the meeting, shareholders proceeded
to elect the below candidates to the Company’s Board of Directors
for a one-year term and elected KPMG LLP, as the Company’s auditors
for the current fiscal year.
All candidates proposed for the position of
directors were elected in the following proportion:
|
# IN FAVOUR |
%IN FAVOUR |
# ABSTENTION |
% ABSTENTION |
|
|
|
|
|
Joseph Arena |
36,236,725 |
94.13 |
2,259,788 |
5.87 |
Gérald A. Lacoste |
29,952,972 |
77.81 |
8,543,541 |
22.19 |
Paul Lévesque |
36,788,358 |
95.56 |
1,708,155 |
4.44 |
Gary Littlejohn |
29,029,970 |
75.41 |
9,466,543 |
24.59 |
Andrew Molson |
33,682,560 |
87.50 |
4,813,953 |
12.50 |
Alain Trudeau |
33,722,300 |
87.60 |
4,774,213 |
12.40 |
Dawn Svoronos |
34,243,837 |
88.95 |
4,252,676 |
11.05 |
Dale MacCandlish-Weil |
33,663,747 |
87.45 |
4,832,766 |
12.55 |
Dawn Svoronos, Chair of the Board and Paul
Lévesque, President and CEO of Theratechnologies, addressed people
who attended the virtual meeting.
“I would like to congratulate Alain Trudeau and
Andrew Molson on their election to the board of directors of
Theratechnologies. Both Alain and Andrew are well-recognized and
respected business leaders with the expertise and vision to support
the Company through its next stage of development and growth. I
also want to welcome Joseph Arena as a new member of the board of
directors of Theratechnologies. Joseph has had an illustrious
career holding various strategic leadership roles in the
pharmaceutical industry, including head of regulatory affairs
across lines of business’ with Merck and Pfizer, respectively. He
brings a strong scientific acumen that will be invaluable to the
Company as we continue to advance the R&D pipeline in Oncology,
NASH and HIV,” said Dawn Svoronos, Chair of the Board,
Theratechnologies.
“I would also like to give a sincere and special
thank you to Paul Pommier and Sheila Frame as they step down from
the Board. Paul, as many of you may know, served on the Board for
nearly 20 years including as Chair from 2007 to 2013. We wish to
thank both of our colleagues for their invaluable contributions to
Theratechnologies,” added Ms. Svoronos.
“We exited 2020 as a stronger, more focused and
aligned organization with a determination to develop our R&D
pipeline while continuing to enhance our commercial HIV franchise.
I am pleased that the momentum and progress that we built in 2020
has carried over with us into the new year,” said Paul Lévesque,
President and CEO, Theratechnologies.
About
TheratechnologiesTheratechnologies (TSX: TH) (NASDAQ:
THTX) is a biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and
forward-looking information, or, collectively, forward-looking
statements, within the meaning of applicable securities laws, that
are based on our management’s beliefs and assumptions and on
information currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", “would”, "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding Theratechnologies’ growth and the
development of Theratechnologies’ pipeline.
Forward-looking statements are based upon a
number of assumptions and include, but are not limited to, the
following: demand for EGRIFTA SV® and Trogarzo® will grow in the
United States and in Europe, no untoward side effects will be
discovered from the long-term use of EGRIFTA SV® and Trogarzo®,
none of those products will be subject to a recall, the U.S. Food
and Drug Administration will approve our final protocol to initiate
our Phase 3 clinical trial in NASH, we will be able to recruit
patients for our Phase 3 clinical trial in NASH, we will be able to
continue the recruitment of patients for our Phase 1 clinical trial
in oncology and results obtained from the conduct of our
pre-clinical studies in oncology will be replicated into human
subjects.
Forward-looking statements are subject to a
variety of risks and uncertainties, many of which are beyond our
control that could cause our actual results to differ materially
from those that are disclosed in or implied by the forward-looking
statements contained in this press release. These risks and
uncertainties include, among others, the risk that demand for our
products decrease over time, that Trogarzo® is not approved for
reimbursement in key European countries, that competition erodes
our market share, that our Phase 3 clinical trail in NASH and our
Phase 1 clinical trial in oncology do not yield positive results,
the effect of which would be to delay or cancel any of those
clinical trials, that untoward side effects resulting from the
long-term use of our products are discovered, that our intellectual
property on tesamorelin is challenged and found to be
unenforceable, and that we face product liability litigations.
We refer current and potential investors to the
“Risk Factors” section of our Annual Information Form dated
February 24, 2021 available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov as an exhibit to our report on Form 40-F dated
February 25, 2021 under Theratechnologies’ public filings. The
reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date.
We undertake no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise, except as may be required by applicable law.
For media inquiries:Denis BoucherVice President,
Communications and Corporate
Affairscommunications@theratech.com514-336-7800
For investor inquiries:Leah GibsonSenior
Director, Investor Relations ir@theratech.com 617-356-1009
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Sep 2023 to Sep 2024